Jose Valdez Madruga
Overview
Explore the profile of Jose Valdez Madruga including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
567
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kelley C, Acevedo-Quinones M, Agwu A, Avihingsanon A, Benson P, Blumenthal J, et al.
N Engl J Med
. 2024 Nov;
PMID: 39602624
Background: Twice-yearly subcutaneous lenacapavir has been shown to be efficacious for prevention of HIV infection in cisgender women. The efficacy of lenacapavir for preexposure prophylaxis (PrEP) in cisgender men, transgender...
2.
Silva M, Torres T, Coutinho C, Moreira R, da Costa Leite I, Cunha M, et al.
Lancet HIV
. 2024 Sep;
11(10):e670-e679.
PMID: 39243787
Background: The global burden of sexually transmitted infections (STIs) poses a challenge in the context of HIV pre-exposure prophylaxis (PrEP) programmes. We aimed to explore factors associated with prevalent, incident,...
3.
Torres T, Teixeira S, Hoagland B, Konda K, Derrico M, Moreira R, et al.
Lancet Reg Health Am
. 2023 Dec;
28:100642.
PMID: 38076411
Background: HIV incidence estimation is critical for monitoring the HIV epidemic dynamics and the effectiveness of public health prevention interventions. We aimed to identify sexual and gender minorities (SGM) with...
4.
Lundgren J, Babiker A, Sharma S, Grund B, Phillips A, Matthews G, et al.
NEJM Evid
. 2023 May;
2(3).
PMID: 37213438
Background: For people with HIV and CD4 counts >500 cells/mm, early initiation of antiretroviral therapy (ART) reduces serious AIDS and serious non-AIDS (SNA) risk compared with deferral of treatment until...
5.
Veloso V, Caceres C, Hoagland B, Moreira R, Vega-Ramirez H, Konda K, et al.
Lancet HIV
. 2022 Dec;
10(2):e84-e96.
PMID: 36565708
Background: Although gay, bisexual, and other cisgender men who have sex with men (MSM) and transgender women have the highest HIV burden in Latin America, pre-exposure prophylaxis (PrEP) implementation is...
6.
Petruccelli K, Baia-da-Silva D, Val F, Valoes M, Cubas-Vega N, Silva-Neto A, et al.
AIDS Res Ther
. 2022 Feb;
19(1):12.
PMID: 35209929
Background: Pre-Exposure Prophylaxis (PrEP) has demonstrated efficacy in the reduction of sexually transmitted HIV infections. The prolonged use of tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) co-formulation (TDF/FTC), however, may...
7.
Marins L, Torres T, Leite I, Moreira R, Luz P, Hoagland B, et al.
PLoS One
. 2019 Aug;
14(8):e0221281.
PMID: 31430318
Introduction: Efficacy of daily emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) for PrEP is strongly dependent on the adherence. We examined the concordance between indirect adherence measures and protective drug levels among participants...
8.
Tan D, Raboud J, Szadkowski L, Grinsztejn B, Valdez Madruga J, Figueroa M, et al.
J Antimicrob Chemother
. 2018 Oct;
74(2):480-488.
PMID: 30376108
Objectives: To determine the impact of valaciclovir on HIV disease progression in treatment-naive HIV-positive adults. Methods: In this fully blind, multicentre, 1:1 randomized placebo-controlled trial, treatment-naive HIV-1-positive adults with CD4...
9.
De Boni R, Machado I, de Vasconcellos M, Hoagland B, Kallas E, Valdez Madruga J, et al.
Drug Alcohol Depend
. 2018 Feb;
185:168-172.
PMID: 29454927
Background: Concurrent psychosocial problems may synergistically increase the risk of HIV infection (syndemics), representing a challenge for prevention. We aimed to evaluate the prevalence and associated factors of syndemics among...
10.
Hoagland B, Moreira R, De Boni R, Kallas E, Valdez Madruga J, Vasconcelos R, et al.
J Int AIDS Soc
. 2017 Apr;
20(1):21472.
PMID: 28418232
Introduction: The efficacy of pre-exposure prophylaxis (PrEP) in preventing sexual acquisition of human immunodeficiency virus (HIV) is well established. Little is known about the feasibility of PrEP implementation in middle-income...